Swiss Healthcare Licensing Group
How can Swiss biotechs remain competitive in a challenging environment for early stage financing and partnering?
After record years of capital investements into biotech companies during the Covid pandemic, the global investment climate for biotech companies has reversed in 2022. The Swiss Venture Capital Report Report 2023 revealed a sharp downturn in biotech investments (back to the average level of 2017-2019), while other sectors improved and reached record highs. This panel will discuss the implications, the wider industry context and how the vibrant Swiss innovation ecosystem can best compete on a global stage, with perspectives from VC, pharma, biotech, Venturelab and the panel host, Swiss HLG.
Sarah Holland, President, Swiss HLG
Jordi Montserrat, Co-Founder and Managing Partner, Venturelab
Veronica Gambillara Fonck, Partner, Pureos Bioventures
Michael Huebner, Director Early Innovation Partnering, Johnson & Johnson
Alexander Breidenbach, CDO/CBO, ACM Biosciences
The Swiss Healthcare Licensing Group is an association of business development professionals, well recognized within the healthcare industry.
Its goal is to provide a unique and inspiring environment for building relationships, sharing best practices and facilitating business interactions.